Opioids Market is witnessing growth due to the increasing prevalence of orthopedic diseases and chronic pain, rising focus on abuse-deterrent formulation (ADF), rising palliative care facilities, and inclination toward extended release formulations from the immediate release of Opioids.
However, factors such as prescription drug abuse, and legalization of cannabis as an alternative to Opioids may hinder the growth of the market in the coming years.
Opioids are a group of narcotic pain-relieving drug which acts by interacting with opioid receptors in cells. Opioids can be made from the poppy plant such as morphine or synthesized in a laboratory such as fentanyl. It is used as anesthesia, cough suppressant, diarrhea suppressant and for the management of pain arising from various disease.
Opioids Market segmentation:
· based on a product.
· based on receptor binding.
· based on application.
· based on regions.
Opioids Market Product And receptor binding:
Based on the product, the market is divided into morphine, codeine, fentanyl, meperidine, methadone, and others. Based on the receptor binding, the market is segmented into strong agonist, and mild to moderate agonist.
Opioids Market by Application:
· Pain Management
1. Cancer Pain
2. Neuropathic Pain
3. Osteoarthritis Pain
· Cough Suppression
· Diarrhea Suppression
The Major Players Operating in the Opioids Market:
The major players in the Infant nutrition market are Purdue Pharma (US), Sanofi (France), Pfizer (US), Janssen Pharmaceuticals (Belgium), Endo Pharmaceuticals, Inc (US), Actavis Plc (US), Egalet (US), Sun Pharmaceuticals (India), and Boehringer Ingelheim GmbH (Germany).
Geographical Detailed Analysis for Opioids Market:
These markets are given analysis at the regional level to provide exhaustive Opioids Market analysis for the years 2016, 2017, 2018, and forecast to 2023.
The Opioids Market is comprehensively analyzed at a granular level by region (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly